论文部分内容阅读
目的:观察格列美脲对于超重2型糖尿病患者是否能够减少胰岛素用量。方法:将28名胰岛素治疗效果不佳的超重2型糖尿病患者随机分为两组,A组继续调整胰岛素用量基础上加用格列美脲2mg,B组单纯调整胰岛素的剂量,均维持治疗12周,GHbAlC≤7.0%,比较两组胰岛素用量及体重变化。结果:在治疗达标12周后,B组胰岛素用量较A组多(P<0.05),体重在两组之间未见明显统计学差异,但B组体重增加较A组略明显。结论:对于超重患者,胰岛素联合格列美脲不但可以使胰岛素增加剂量的幅度减少,而且对控制体重起到有益作用。
OBJECTIVE: To investigate whether glimepiride can reduce insulin dosage in overweight type 2 diabetic patients. Methods: Twenty-eight patients with type 2 diabetes who had poor insulin treatment were randomly divided into two groups: Group A continued to adjust insulin dosage based on the use of glimepiride 2mg; Group B only adjusted insulin dose and maintained 12 Weeks, GHbAlC≤7.0%, comparing insulin dosage and body weight changes in two groups. Results: After 12 weeks of treatment, the dosage of insulin in group B was more than that in group A (P <0.05). There was no significant difference in body weight between the two groups. However, the weight gain in group B was slightly more than that in group A. CONCLUSIONS: In patients with overweight, insulin plus glimepiride not only increased insulin dose but also played a beneficial role in weight control.